Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Raised to $25.00 at JMP Securities

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target boosted by research analysts at JMP Securities from $24.00 to $25.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price objective would indicate a potential upside of 229.82% from the stock’s current price.

A number of other brokerages have also weighed in on ENTA. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. HC Wainwright assumed coverage on shares of Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a “buy” rating and a $20.00 price target on the stock.

Enanta Pharmaceuticals Stock Performance

ENTA stock opened at $7.58 on Tuesday. The stock has a market capitalization of $162.06 million, a P/E ratio of -1.75 and a beta of 0.88. Enanta Pharmaceuticals has a one year low of $4.09 and a one year high of $13.43. The company has a 50 day moving average price of $7.37 and a two-hundred day moving average price of $6.45.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.40. The firm had revenue of $18.31 million during the quarter, compared to analysts’ expectations of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. Research analysts forecast that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ENTA. US Bancorp DE acquired a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at $36,000. GAMMA Investing LLC acquired a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at $40,000. Tower Research Capital LLC TRC lifted its holdings in shares of Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 2,274 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 5,779 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at $66,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.